Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution1 total trials
Phase 2Efficacy & side effects
1(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(2)

Detailed Status

Completed2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 21 (100.0%)

Trials by Status

completed267%
active_not_recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
completed

H. Pylori Infection and AIP Levels

NCT07306377
active_not_recruiting

Validation of a Molecular Test for Risk-stratification of Patients With High-risk Intestinal Metaplasia (GCEP2 Study)

NCT05782465
completedphase_2

Pepsinogens as the Early Marker of H. Pylori Eradication

NCT00197457

Clinical Trials (3)

Showing 3 of 3 trials
NCT07306377

H. Pylori Infection and AIP Levels

Completed
NCT05782465

Validation of a Molecular Test for Risk-stratification of Patients With High-risk Intestinal Metaplasia (GCEP2 Study)

Active Not Recruiting
NCT00197457Phase 2

Pepsinogens as the Early Marker of H. Pylori Eradication

Completed

All 3 trials loaded

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
3